Search results for "Tumor necrosis factor-alpha"

showing 10 items of 504 documents

Splenic Littoral Cell Hemangioendothelioma in a Patient With Crohn's Disease Previously Treated With Immunomodulators and Anti-TNF Agents: A Rare Tum…

2011

Th e risk of malignancy in Crohn ’ s disease (CD) has been well described. Moreover, immunomodulators, uch as azathioprine (AZA) and 6-mercaptopurine (6-MP), and biological agents, such as infl iximab and adalimumab, may promote carcinogenesis ( 1 – 3 ). Splenic littoral cell tumors are recently described tumors of vascular origin composed of endothelial cells, with typical microscopic and immunohistochemical features of splenic sinus lining cells ( 4 ). Clinical findings are not specific, and outcome is unpredictable but usually benign, although a few cases with a malignant behavior have been reported ( 5,6 ). We report a 58-year-old Caucasian man with a long history of ileocolonic CD.

6-MercaptopurineMalePathologymedicine.medical_specialtyColonic Diseasemedicine.medical_treatmentAzathioprineSplenic NeoplasmHemangioendotheliomaHemangiomaImmunosuppressive AgentImmunocompromised HostImmunologic FactorCrohn Disease6-Mercaptopurine; Azathioprine; Colonic Diseases; Crohn Disease; Gastrointestinal Agents; Hemangioendothelioma; Hemangioma; Humans; Ileal Diseases; Immunologic Factors; Immunosuppressive Agents; Male; Middle Aged; Splenic Neoplasms; Tumor Necrosis Factor-alpha; Immunocompromised Host; GastroenterologyAzathioprineGastrointestinal AgentMedicineGastrointestinal agentCrohn's diseaseHepatologyTumor Necrosis Factor-alphabusiness.industryGastroenterologyImmunosuppressionMiddle Agedmedicine.diseaseSplenic NeoplasmHemangioendotheliomaImmunologyIleal DiseaseTumor necrosis factor alphaHemangiomabusinessHumanmedicine.drugAmerican Journal of Gastroenterology
researchProduct

Lung CD11c+ cells from mice deficient in Epstein-Barr virus-induced gene 3 (EBI-3) prevent airway hyper-responsiveness in experimental asthma

2007

Epstein-Barr virus-induced gene (EBI)-3 codes for a soluble type 1 cytokine receptor homologous to the p40 subunit of IL-12 that is expressed by antigen-presenting cells following activation. Here, we analyzed the functional role of EBI-3 in a murine model of asthma associated with airway hyper-responsiveness (AHR) in ovalbumin-sensitized mice. Upon allergen challenge, EBI-3-/- mice showed less severe AHR, decreased numbers and degranulation of eosinophils and a significantly reduced number of VCAM-1+ cells in the lungs as compared to wild-type littermates. We thus analyzed lung CD11c+ cells before and after allergen challenge in these mice and found that before allergen challenge, lung CD1…

Adoptive cell transferMyeloidCell TransplantationImmunologyVascular Cell Adhesion Molecule-1CD11cCD8-Positive T-LymphocytesBiologyMinor Histocompatibility AntigensInterferon-gammaMiceImmune systemmedicineAnimalsImmunology and AllergyReceptors CytokineLungCell ProliferationMice KnockoutLungTumor Necrosis Factor-alphaEffectorDegranulationInterferon-alphaDendritic CellsSTAT4 Transcription Factorrespiratory systemInterleukin-12AsthmaCD11c AntigenInterleukin-10respiratory tract diseasesEosinophilsMice Inbred C57BLmedicine.anatomical_structureImmunologyInterleukin-4Bronchial HyperreactivityInterleukin-5T-Box Domain ProteinsCytokine receptorBronchoalveolar Lavage FluidEuropean Journal of Immunology
researchProduct

Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation.

2012

Adoptive cell transfer therapies (ACTs) with cytotoxic T cells that target melanocytic antigens can achieve remissions in patients with metastatic melanomas, but tumours frequently relapse. Hypotheses explaining the acquired resistance to ACTs include the selection of antigen-deficient tumour cell variants and the induction of T-cell tolerance. However, the lack of appropriate experimental melanoma models has so far impeded clear insights into the underlying mechanisms. Here we establish an effective ACT protocol in a genetically engineered mouse melanoma model that recapitulates tumour regression, remission and relapse as seen in patients. We report the unexpected observation that melanoma…

Adoptive cell transfermedicine.medical_treatmentCellular differentiationT cellBiologyProinflammatory cytokineMiceAntigenCell Line TumormedicineTumor MicroenvironmentCytotoxic T cellAnimalsHumansMelanomaCell ProliferationInflammationMultidisciplinaryTumor Necrosis Factor-alphaMelanomaCell DifferentiationImmunotherapyCell Dedifferentiationmedicine.diseaseAdoptive TransferMice Inbred C57BLDisease Models Animalmedicine.anatomical_structureImmunologyImmunotherapyNeoplasm TransplantationT-Lymphocytes Cytotoxicgp100 Melanoma AntigenNature
researchProduct

Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection.

2008

The prevalence of concurrent rheumatoid arthritis (RA) and hepatitis C virus (HCV) infection is probably underestimated because of the increasing spread of this virus worldwide, especially in developing countries. In these patients, anti-tumor necrosis factor-alpha (anti-TNF-alpha) therapy may aggravate hepatitis and increase viremia. We evaluated the safety of these treatments, which remain controversial.Thirty-one HCV-positive patients (23 women, 8 men, mean age 59+/-13 yrs, mean disease duration 13+/-11.5 SD yrs) with active RA [Disease Activity Score 28 (DAS28)3.2] unresponsive to conventional therapies were treated with TNF-alpha blockers (infliximab 11, etanercept 17, adalimumab 3) at…

AdultAged 80 and overMalerheumatoid arthritissafetyhepatitis c virus; rheumatoid arthritis; safety; tumor necrosis factor-α blockerTumor Necrosis Factor-alphaAdalimumabHepatitis C ChronicMiddle AgedViral Loadhepatitis c virusInfliximabEtanerceptArthritis Rheumatoidtumor necrosis factor-α blockerAdalimumab Etanercept InfliximabAntirheumatic AgentsHumansFemaleanti-tumor necrosis factor-alpha; rheumatoid arthritis; hepatitis CAgedFollow-Up StudiesRetrospective Studies
researchProduct

Modulation of adipokines and cytokines in gestational diabetes and macrosomia.

2006

Abstract Context/Objective: Not much is known about the implication of adipokines and different cytokines in gestational diabetes mellitus (GDM) and macrosomia. The purpose of this study was to assess the profile of these hormones and cytokines in macrosomic babies, born to gestational diabetic women. Design/Subjects: A total of 59 women (age, 19–42 yr) suffering from GDM with their macrosomic babies (4.35 ± 0.06 kg) and 60 healthy age-matched pregnant women and their newborns (3.22 ± 0.08 kg) were selected. Methods: Serum adipokines (adiponectin and leptin) were quantified using an obesity-related multiple ELISA microarray kit. The concentrations of serum cytokines were determined by ELISA…

AdultBlood GlucoseLeptinMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismClinical BiochemistryAdipokineBiochemistryProinflammatory cytokineFetal MacrosomiaInterferon-gammaEndocrinologyAldesleukinPregnancyInternal medicineDiabetes mellitusFetal macrosomiaMedicineHumansInsulinAdiponectinbusiness.industryInterleukin-6Tumor Necrosis Factor-alphaLeptinBiochemistry (medical)Infant Newbornmedicine.diseaseLipidsGestational diabetesDiabetes GestationalEndocrinologyCytokinesInterleukin-2FemaleAdiponectinInterleukin-4businessThe Journal of clinical endocrinology and metabolism
researchProduct

Predictors of insulin resistance in patients with obesity: a pilot study.

2012

We compared adipokines and inflammatory markers in obese insulin-sensitive (group A, n = 16) and insulin-resistant (group B, n = 48) patients divided according to homeostasis model assessment of insulin resistance (HOMA-IR). Serum levels of adiponectin, leptin, resistin, high-sensitivity C-reactive protein, interleukin 6, and tumor necrosis factor α were measured. Weight, height, waist (WC) and hip circumferences, waist to hip ratio , weight to height ratio, visceral adiposity index (VAI), and body adiposity index (BAI) were measured. The WC and VAI were significantly higher in group B (113.9 ± 11.1 vs 105.3 ± 9.8cm; P < .01 and 2.3 ± 1.1 vs 1.6 ± 0.9; P < .05, respectively), while s…

AdultBlood GlucoseLeptinMalemedicine.medical_specialtyWaistAdipokinePilot ProjectsBody adiposity indexBody Mass IndexWaist–hip ratioInsulin resistanceInternal medicinemedicineHumansResistinObesityAgedAdiponectinbusiness.industryInterleukin-6Tumor Necrosis Factor-alphaLeptinMiddle Agedmedicine.diseaseEndocrinologyC-Reactive ProteinResistinFemaleAdiponectinInsulin ResistanceCardiology and Cardiovascular Medicinebusinesscytokines inflammatory markers insulin resistance obesity obesity indicesBiomarkersAngiology
researchProduct

Phase I trial of recombinant human tumour necrosis factor alpha in patients with advanced malignancy.

1991

A phase I clinical trial was conducted with recombinant human tumour necrosis factor alpha (rhTNF-alpha) in 62 patients with advanced malignancy refractory to previous standard therapy. rhTNF-alpha was given as a 30 min infusion twice a day at 6 h intervals. A total of 10 different dose levels was escalated in cohorts of 6 patients ranging from 2.5 to 200 micrograms/m2 twice a day for 5 days every second week for a total of 8 weeks followed by a 4-week observation period. Major side-effects of TNF-alpha therapy, seen in almost all patients studied, were fever and chills. As dose-limiting side-effects hypotension and liver toxicity were recorded in 4 of 5 patients treated with 200 micrograms…

AdultBlood PlateletsMalemedicine.medical_specialtyNecrosisAdolescentFeverPhases of clinical researchBlood PressureMalignancyGastroenterologyHemoglobinsLeukocyte CountPharmacokineticsRefractoryInternal medicineNeoplasmsmedicineLeukocytesHumansAgedbiologyDose-Response Relationship Drugbusiness.industryPlatelet CountTumor Necrosis Factor-alphaMiddle Agedmedicine.diseaseRecombinant ProteinsSurgeryOncologybiology.proteinDrug EvaluationTumor necrosis factor alphaChillsFemaleAntibodymedicine.symptombusinessEuropean journal of cancer (Oxford, England : 1990)
researchProduct

The A allele of cluster of differentiation 36 (CD36) SNP 1761667 associates with decreased lipid taste perception in obese Tunisian women.

2015

Recent studies have suggested that excessive intake of dietary fat is associated with obesity. Some obese subjects have been reported to exhibit high thresholds for the gustatory detection of lipids via lipid receptors, such as cluster of differentiation 36 (CD36). We studied lingual detection thresholds for emulsions containing oleic acid in obese Tunisian women (n203) using a three-alternative forced choice (3-AFC) method. Genotyping of theTNF-α(rs1800629),IL-6(rs1800795) andCD36(rs1761667) genes was performed to associate with lipid taste perception thresholds. TheCD36genotype distribution was as follows: GG (n42), AG (n102) and AA (n59). Women with theCD36GG genotype exhibited oral dete…

AdultCD36 AntigensTastemedicine.medical_specialtyTunisiaGenotypeCD36Medicine (miscellaneous)Administration OralBiologyPolymorphism Single Nucleotidechemistry.chemical_compoundFood PreferencesInternal medicineGenotypemedicineSNPCluster AnalysisHumansObesityAllele10. No inequalityGenotypingAllelesGeneticsNutrition and DieteticsInterleukin-6Tumor Necrosis Factor-alphaTaste PerceptionMiddle Agedmedicine.diseaseTaste BudsObesityDietary FatsOleic acidEndocrinologychemistryTastebiology.proteinFemaleOleic AcidThe British journal of nutrition
researchProduct

Increased frequency of proinflammatory CD4 T cells and pathological levels of serum neurofilament light chain in adult drug-resistant epilepsy

2020

OBJECTIVE: Adult drug-resistant epilepsy (DRE) is associated with significant morbidity. Infiltration of immune cells is observed in DRE epileptic foci; however, the relation between DRE and the peripheral immune cell compartment remains only partially understood. We aimed to investigate differences in immune cell populations, cytokines, and neurodegenerative biomarkers in the peripheral blood of subjects with epilepsy versus healthy controls, and in DRE compared to well-controlled epilepsy (WCE). METHODS: Peripheral blood mononuclear cells and serum from >120 age- and sex-matched adults suffering from focal onset epilepsy and controls were analyzed by multipanel flow cytometry, multiplex i…

AdultCD4-Positive T-LymphocytesMale0301 basic medicineDrug Resistant Epilepsymedicine.medical_treatmenturologic and male genital diseasesPeripheral blood mononuclear cellProinflammatory cytokineInterferon-gammaYoung Adult03 medical and health sciencesEpilepsyTh2 Cells0302 clinical medicineImmune systemNeurofilament ProteinsmedicineHumansImmunoassayInflammationEpilepsyTumor Necrosis Factor-alphabusiness.industryInterleukinsInterleukin-17NeurotoxicityGranulocyte-Macrophage Colony-Stimulating FactorInterleukinMiddle AgedFlow Cytometrymedicine.diseaseSingle Molecule ImagingCD4 Lymphocyte CountInterleukin-10030104 developmental biologyCytokineNeurologyCase-Control StudiesImmunologyCytokinesTh17 CellsFemaleTumor necrosis factor alphaInterleukin-4Neurology (clinical)business030217 neurology & neurosurgery
researchProduct

Long-term anti-tumour necrosis factor therapy reverses the progression of carotid intima–media thickness in female patients with active rheumatoid ar…

2009

The objective of the study is to evaluate the effect of TNF inhibition on carotid thickness over a 2-year period. 144 women with RA diagnosed according to ACR criteria, without clinical evidence of cardiac and/or vascular disease were enrolled and compared with 78 matched controls. All patients received methotrexate (15–20 mg weekly) for 3 months. Responders (n = 79) continued to be treated with methotrexate, non-responders (n = 40) moved to methotrexate plus a TNF alpha antagonist. Echosonographic studies of carotids were obtained before and after 2-year follow-up. A significant decrease of ca-IMT was observed in anti-TNF-treated patients (P < 0.001); on the other hand, no significant vari…

AdultCarotid Artery Diseasesmedicine.medical_specialtyImmunologyTNFGastroenterologyArthritis RheumatoidRheumatologyInternal medicineRheumatoid arthritis TNF DMARDs AtherosclerosisFemale patientmedicineHumansImmunology and AllergyRheumatoid arthritiUltrasonographyTumor Necrosis Factor-alphaVascular diseasebusiness.industryAntagonistMiddle AgedAtherosclerosismedicine.diseaseRheumatologySurgerySettore MED/16 - ReumatologiaDMARDMethotrexateTreatment OutcomeIntima-media thicknessAntirheumatic AgentsRheumatoid arthritiscardiovascular systemDrug Therapy CombinationFemaleMethotrexateTumor necrosis factor alphaTunica IntimaTunica Mediabusinessmedicine.drugRheumatology International
researchProduct